174 related articles for article (PubMed ID: 29935955)
1. Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis.
Nguyen DX; Cotton A; Attipoe L; Ciurtin C; Doré CJ; Ehrenstein MR
J Allergy Clin Immunol; 2018 Sep; 142(3):978-980.e9. PubMed ID: 29935955
[No Abstract] [Full Text] [Related]
2. F-18 fluorodeoxyglucose positron emission tomography can detect early response to adalimumab, a tumor necrosis factor-α antagonist, in rheumatoid arthritis: A prospective pilot study.
Edupuganti SR; Eder V; Ternant D; Courtehoux M; Tranquart F; Goupille P; Paintaud G; Mulleman D
Joint Bone Spine; 2015 Oct; 82(5):381-3. PubMed ID: 25776440
[No Abstract] [Full Text] [Related]
3. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
[No Abstract] [Full Text] [Related]
4. Have we had a paradigm change in the treatment of rheumatoid arthritis after the American Congress of Rheumatology 2015?
Bukhari M
Rheumatology (Oxford); 2016 Sep; 55(9):1531-3. PubMed ID: 26935649
[No Abstract] [Full Text] [Related]
5. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
[TBL] [Abstract][Full Text] [Related]
6. Melanocortin 2, 3 and 4 Receptor Gene Expressions are Downregulated in CD8
Andersen M; Nagaev I; Meyer MK; Nagaeva O; Wikberg J; Mincheva-Nilsson L; Andersen GN
Scand J Immunol; 2017 Jul; 86(1):31-39. PubMed ID: 28426141
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.
Tweehuysen L; Schraa K; Netea MG; van den Hoogen FHJ; Joosten LAB; den Broeder AA
Clin Exp Rheumatol; 2018; 36(1):140-143. PubMed ID: 29148425
[TBL] [Abstract][Full Text] [Related]
8. The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation.
Lin YC; Lin YC; Wu CC; Huang MY; Tsai WC; Hung CH; Kuo PL
Oncotarget; 2017 Jan; 8(5):7559-7571. PubMed ID: 27926504
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
Nakayamada S; Kubo S; Yoshikawa M; Miyazaki Y; Yunoue N; Iwata S; Miyagawa I; Hirata S; Nakano K; Saito K; Tanaka Y
Rheumatology (Oxford); 2018 Jan; 57(1):164-174. PubMed ID: 28371836
[TBL] [Abstract][Full Text] [Related]
10. Low Percentage of Signal Regulatory Protein α/β
Magill L; Adriani M; Berthou V; Chen K; Gleizes A; Hacein-Bey-Abina S; Hincelin-Mery A; Mariette X; Pallardy M; Spindeldreher S; Szely N; Isenberg DA; Manson JJ; Jury EC; Mauri C
Front Immunol; 2018; 9():2865. PubMed ID: 30568660
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with photodynamic therapy in a patient with nasal mucocutaneous leishmaniasis undergoing treatment with TNFα inhibitor.
Cerro PA; Sánchez-Hernández M; Morales-Callaghan AM; Estrada-Mallarino N; Gilaberte Y
Eur J Dermatol; 2020 Dec; 30(6):750-751. PubMed ID: 33331279
[No Abstract] [Full Text] [Related]
12. Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activity.
Heftdal LD; Stengaard-Pedersen K; Ørnbjerg LM; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B; Møller HJ; Greisen SR
Scand J Clin Lab Invest; 2017 Sep; 77(5):385-389. PubMed ID: 28598681
[TBL] [Abstract][Full Text] [Related]
13. TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis.
Lieberman MR; Liebman TN; Alapati U; Khachemoune A
Dermatol Online J; 2014 Dec; 21(2):. PubMed ID: 25756476
[TBL] [Abstract][Full Text] [Related]
14. Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis.
Eektimmerman F; Swen JJ; Böhringer S; Huizinga TW; Kooloos WM; Allaart CF; Guchelaar HJ
Pharmacogenomics; 2017 Jul; 18(10):945-953. PubMed ID: 28639493
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism of action of biological disease--modifying antirheumatic drugs].
Takahashi N; Ishiguro N
Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
[No Abstract] [Full Text] [Related]
16. Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.
Mengato D; Messori A
Clin Exp Rheumatol; 2018; 36(6):1118. PubMed ID: 29600941
[No Abstract] [Full Text] [Related]
17. Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis.
Dombrecht EJ; Aerts NE; Schuerwegh AJ; Hagendorens MM; Ebo DG; Van Offel JF; Bridts CH; Stevens WJ; De Clerck LS
Clin Exp Rheumatol; 2006; 24(1):31-7. PubMed ID: 16539816
[TBL] [Abstract][Full Text] [Related]
18. Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure.
Martínez Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; Nozal P; Ángeles González M; Nuño L; Monjo I; Pascual-Salcedo D; Balsa A
Semin Arthritis Rheum; 2020 Feb; 50(1):E1-E2. PubMed ID: 31375255
[No Abstract] [Full Text] [Related]
19. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis.
Krintel SB; Dehlendorff C; Hetland ML; Hørslev-Petersen K; Andersen KK; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard HM; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Jørgensen A; Raun J; Ammitzbøll CG; Østergaard M; Stengaard-Pedersen K; Johansen JS
Pharmacogenomics J; 2016 Apr; 16(2):141-6. PubMed ID: 25939484
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour necrosis factor α-induced lupus erythematosus panniculitis.
Durand AL; Goussot JF; Thiolat D; Taieb A; Marie J; Seneschal J; Darrigade AS
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):e318-e319. PubMed ID: 28045205
[No Abstract] [Full Text] [Related]
[Next] [New Search]
